Castle Biosciences, Inc. (CSTL)
Runs genetic tests that predict cancer risk for skin and esophageal patients.
$24.20-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+65.2%
The outlook
CSTL trades near the lower end of its 52-week range, with analysts showing strong conviction—the average price target sits about 77% above the current price. The stock's price trend against moving averages is mixed, suggesting some near-term uncertainty despite the bullish analyst consensus. Overall sentiment leans bullish based on the combination of strong buy ratings and the gap between current price and targets.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 9 analysts
Price trendMixed vs its moving averages
52-week range32% of the way from its 52-week low to high
Price targetAvg target +77% vs current price
Analyst price target
~12-month · 9 analysts$42.78average target+76.8% vs now
Now $24.20
Low $35.00High $52.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$733.8M
52-wk high
$44.28
52-wk low
$14.59
50-day avg
$22.13
200-day avg
$28.81
Trailing P/E
—